Journal ArticleDOI
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida,Hiroshi Nokihara,Masashi Kondo,Young Hak Kim,Koichi Azuma,Takashi Seto,Yuichi Takiguchi,Makoto Nishio,Hiroshige Yoshioka,Fumio Imamura,Katsuyuki Hotta,Satoshi Watanabe,Koichi Goto,Miyako Satouchi,Toshiyuki Kozuki,Takehito Shukuya,Kazuhiko Nakagawa,Tetsuya Mitsudomi,Nobuyuki Yamamoto,Takashi Asakawa,Ryoichi Asabe,Tomohiro Tanaka,Tomohide Tamura +22 more
Reads0
Chats0
TLDR
These results provide the first head-to-head comparison of alectinib and crizotinib and have the potential to change the standard of care for the first-line treatment of ALK-positive non-small-cell lung cancer.About:
This article is published in The Lancet.The article was published on 2017-07-01. It has received 665 citations till now. The article focuses on the topics: Alectinib & Crizotinib.read more
Citations
More filters
Journal ArticleDOI
Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions.
Julien Ancel,Maxime Dewolf,Gaëtan Deslée,Béatrice Nawrocky-Raby,Véronique Dalstein,Christine Gilles,Myriam Polette +6 more
TL;DR: Clinical and histological features of non-small-cell lung cancer associated with EMT are reviewed and potential clinical implications of EMT in current therapeutic options are established, including surgery, radiation, targeted therapy against oncogenic drivers, and immunotherapy.
Journal ArticleDOI
Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
TL;DR: The efficacy, indications, and degree of CNS penetration for the ALK-targeting agents crizotinib, ceretinib, alectinib, brigatinib, and lorlatinib are reviewed, as well as a summary of ongoing clinical trials comparing these drugs.
Journal ArticleDOI
Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer.
Elisabeth Smolle,Valentin Taucher,Joerg Lindenmann,Philipp J. Jost,Martin Pichler,Martin Pichler +5 more
TL;DR: A review of the literature on resistance mechanisms to ALK-TKIs in non-small cell lung cancer (NSCLC) is presented in this paper, where the authors aim at providing an overview of current knowledge about resistance mechanisms.
Journal ArticleDOI
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis.
Filipe Cirne,Shijie Zhou,Coralea Kappel,Adam El-Kadi,Carly Barron,Peter M. Ellis,Stephanie Sanger,Darryl P. Leong,Darryl P. Leong,Darryl P. Leong +9 more
TL;DR: In this article, the risk of bradycardia associated with ALK inhibitors in patients with advanced non-small cell lung cancer (NSCLC) was determined by a systematic search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, National clinical trial registry, and Web of Science Core Collection.
Journal ArticleDOI
Anti-PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status.
Taichi Matsubara,Takashi Seto,Shinkichi Takamori,Takatoshi Fujishita,Ryo Toyozawa,Kensaku Ito,Masafumi Yamaguchi,Tatsuro Okamoto +7 more
TL;DR: In this paper, the therapeutic effect of anti-programmed death 1 (PD-1) antibodies for patients with advanced non-small cell lung cancer (NSCLC) on the basis of global Phase III trials was examined.
References
More filters
Journal ArticleDOI
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Manabu Soda,Young Lim Choi,Munehiro Enomoto,Shuji Takada,Yoshihiro Yamashita,Shunpei Ishikawa,Shin-ichiro Fujiwara,Hideki Watanabe,Kentaro Kurashina,Hisashi Hatanaka,Masashi Bando,Shoji Ohno,Yuichi Ishikawa,Hiroyuki Aburatani,Toshiro Niki,Yasunori Sohara,Yukihiko Sugiyama,Hiroyuki Mano +17 more
TL;DR: It is shown that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.
Journal ArticleDOI
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw,Dong Wan Kim,Kazuhiko Nakagawa,Takashi Seto,Lucio Crinò,Myung-Ju Ahn,Tommaso De Pas,Benjamin Besse,Benjamin Solomon,Fiona H Blackhall,Yi-Long Wu,Michael Thomas,Kenneth J. O'Byrne,Denis Moro-Sibilot,D. Ross Camidge,Tony Mok,Vera Hirsh,Gregory J. Riely,Shrividya Iyer,V. Tassell,Anna Polli,Keith D. Wilner,Pasi A. Jänne +22 more
TL;DR: Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement and greater improvement in global quality of life with crizotinIB than with chemotherapy.
Journal ArticleDOI
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
Benjamin Solomon,Tony Mok,Dong Wan Kim,Yi-Long Wu,Kazuhiko Nakagawa,Tarek Mekhail,Enriqueta Felip,Federico Cappuzzo,Jolanda Paolini,Tiziana Usari,Shrividya Iyer,Arlene Reisman,Keith D. Wilner,Jennifer M. Tursi,Fiona H Blackhall +14 more
TL;DR: Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC and was associated with greater reduction in lung cancer symptoms and greater improvement in quality of life.
Journal ArticleDOI
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Klarisa Rikova,Ailan Guo,Qingfu Zeng,Anthony Possemato,Jian Yu,Herbert Haack,Julie Nardone,Kimberly Lee,Cynthia Reeves,Yu Li,Yerong Hu,Zhi-Ping Tan,Matthew P. Stokes,Laura Sullivan,Jeffrey Mitchell,Randy Wetzel,Joan MacNeill,Jian Min Ren,Jin Yuan,Corey E. Bakalarski,Judit Villén,Jon M. Kornhauser,Bradley L. Smith,Daiqiang Li,Xinmin Zhou,Steven P. Gygi,Ting-Lei Gu,Roberto D. Polakiewicz,John Rush,Michael J. Comb +29 more
TL;DR: By focusing on activated cell circuitry, the approach outlined here provides insight into cancer biology not available at the chromosomal and transcriptional levels and can be applied broadly across all human cancers.
Journal ArticleDOI
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel,Leena Gandhi,Gregory J. Riely,Alberto Chiappori,Howard West,Michele C. Azada,Peter N. Morcos,Ruey Min Lee,Linta Garcia,Li Yu,Frederic Boisserie,Laura Di Laurenzio,Sophie Golding,Jotaro Sato,Shumpei Yokoyama,Tomohiro Tanaka,Sai-Hong Ignatius Ou +16 more
TL;DR: Alectinib was well tolerated, with promising antitumour activity in patients with ALK-rearranged NSCLC resistant to crizotinib, including those with CNS metastases.
Related Papers (5)
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw,Dong Wan Kim,Kazuhiko Nakagawa,Takashi Seto,Lucio Crinò,Myung-Ju Ahn,Tommaso De Pas,Benjamin Besse,Benjamin Solomon,Fiona H Blackhall,Yi-Long Wu,Michael Thomas,Kenneth J. O'Byrne,Denis Moro-Sibilot,D. Ross Camidge,Tony Mok,Vera Hirsh,Gregory J. Riely,Shrividya Iyer,V. Tassell,Anna Polli,Keith D. Wilner,Pasi A. Jänne +22 more
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Jean-Charles Soria,Yuichiro Ohe,Johan Vansteenkiste,Thanyanan Reungwetwattana,Busyamas Chewaskulyong,Ki Hyeong Lee,Arunee Dechaphunkul,Fumio Imamura,Naoyuki Nogami,Takayasu Kurata,Isamu Okamoto,Caicun Zhou,Byoung Chul Cho,Ying Cheng,Eun Kyung Cho,Pei Jye Voon,David Planchard,Wu Chou Su,Jhanelle E. Gray,Siow-Ming Lee,Rachel Hodge,Marcelo Marotti,Yuri Rukazenkov,Suresh S. Ramalingam +23 more